DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

Equities research analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Thursday. The brokerage set a “hold” rating on the stock.

Other research analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of DBV Technologies in a research report on Thursday, August 1st. JMP Securities increased their price objective on DBV Technologies from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research report on Wednesday, July 31st.

DBV Technologies Price Performance

DBV Technologies stock opened at $0.75 on Thursday. DBV Technologies has a 12 month low of $0.50 and a 12 month high of $2.92. The business has a 50 day simple moving average of $0.87 and a 200-day simple moving average of $1.11. The stock has a market capitalization of $72.23 million, a PE ratio of -0.89 and a beta of 0.68.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The business had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same quarter in the previous year, the company posted ($0.26) EPS. As a group, equities research analysts anticipate that DBV Technologies will post -1.43 EPS for the current year.

Institutional Trading of DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the period. DBV Technologies accounts for approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.